Farringdon Capital, Ltd. Editas Medicine, Inc. Transaction History
Farringdon Capital, Ltd.
- $198 Billion
- Q1 2025
A detailed history of Farringdon Capital, Ltd. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Farringdon Capital, Ltd. holds 16,327 shares of EDIT stock, worth $22,857. This represents 0.01% of its overall portfolio holdings.
Number of Shares
16,327Holding current value
$22,857% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding EDIT
# of Institutions
218Shares Held
46.4MCall Options Held
436KPut Options Held
324K-
Black Rock Inc. New York, NY7.78MShares$10.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.47MShares$10.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.66MShares$3.72 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.94MShares$2.72 Million0.0% of portfolio
-
State Street Corp Boston, MA1.85MShares$2.58 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $96.2M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...